Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has received a $120,000 G-Rex® grant from ScaleReady, Wilson Wolf Manufacturing, and Cell Ready to enhance the manufacturing process of its lead CAR-T product candidate, HG-CT-1, which is in Phase I trials for relapsed/refractory acute myeloid leukemia. The grant will support the development of a closed-system manufacturing platform to reduce costs and improve regulatory compliance, crucial for the commercial viability of CAR-T therapies. This collaboration is expected to strengthen Hemogenyx’s manufacturing capacity and support the adoption of advanced bioreactor systems, positioning the company for future clinical and commercial success.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the curative potential of bone marrow transplantation for patients with otherwise incurable life-threatening conditions. Hemogenyx is working on several product candidates and a platform technology for novel product development.
Average Trading Volume: 36,143
Technical Sentiment Signal: Sell
Current Market Cap: £6.52M
For an in-depth examination of HEMO stock, go to TipRanks’ Overview page.